 Shares of Omeros NASDAQ: OMER fell as much as 13.3 today after the company announced the pricing of a public offering of common stock and more details about a debt offering. The biopharma will offer up to 7.9 million shares of common stock at 14.50 apiece, which would haul in gross proceeds of roughly 115 million. Investors are displeased that the offering price is far below the 20-plus mark shares soared to after the company reported encouraging results from a six-patient study in COVID-19-associated acute respiratory distress syndrome ARDS. 